Key result
Novel biological markers characterizing right ventricular dysfunction are reviewed for their potential to improve the diagnosis and mortality risk stratification of patients with pulmonary embolism.
Why the study?
Current laboratory parameters for venous thromboembolism and pulmonary embolism have low specificity, creating an urgent need for new biomarkers to improve detection and risk stratification.
This review highlights the potential of novel biomarkers to improve the diagnosis and risk stratification of patients with pulmonary embolism beyond current standard tests like D-dimer and troponin.
Answers are grounded in this paper and cite their sources.
Novel RV dysfunction biomarkers in PE remain hypothesis-generating; prospective validation required before clinical adoption.
Pulmonary embolism (PE) ranks third in the structure of death causes among all cardiovascular diseases after myocardial infarction and stroke. That is why the timely and earliest possible diagnosis of venous thromboembolism is of particular importance, which will help improve both short-term and long-term patient prognosis. Given the low specificity of current laboratory parameters, such as D-dimer, NT-proBNP, cardiac troponin I, there is an urgent need to search for new biomarkers that can improve the quality of detection and stratification of VTE, including PE. A diagnostic and prognostic test for PE must be accurate, safe, easily accessible and inexpensive, as well as reproducible and non-invasive. This review presents the currently available literature data on the latest laboratory parameters that characterize right ventricular dysfunction due to PE and provide an evidence base for stratification of the death risk in this category of patients.
No takes yet. Share an insight, caveat, or question.
Podlipaeva et al. (2021) conducted a review in Pulmonary embolism. Novel biological markers was evaluated. Novel biological markers characterizing right ventricular dysfunction are reviewed for their potential to improve the diagnosis and mortality risk stratification of patients with pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: